1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > nLife Therapeutics, S.L. - Product Pipeline Review - 2015

nLife Therapeutics, S.L. - Product Pipeline Review - 2015

  • October 2015
  • -
  • Global Markets Direct
  • -
  • 26 pages

nLife Therapeutics, S.L. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘nLife Therapeutics, S.L. - Product Pipeline Review - 2015’, provides an overview of the nLife Therapeutics, S.L.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of nLife Therapeutics, S.L.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of nLife Therapeutics, S.L. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of nLife Therapeutics, S.L.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the nLife Therapeutics, S.L.’s pipeline products

Reasons to buy

- Evaluate nLife Therapeutics, S.L.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of nLife Therapeutics, S.L. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the nLife Therapeutics, S.L.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of nLife Therapeutics, S.L. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of nLife Therapeutics, S.L.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of nLife Therapeutics, S.L. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

nLife Therapeutics, S.L. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
nLife Therapeutics, S.L. Snapshot 5
nLife Therapeutics, S.L. Overview 5
Key Information 5
Key Facts 5
nLife Therapeutics, S.L. - Research and Development Overview 6
Key Therapeutic Areas 6
nLife Therapeutics, S.L. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
nLife Therapeutics, S.L. - Pipeline Products Glance 10
nLife Therapeutics, S.L. - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Discovery Products/Combination Treatment Modalities 11
nLife Therapeutics, S.L. - Drug Profiles 12
NLF-MO 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
NLF-NEU 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
NLFPD-1233 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
OL-1 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Antisense Oligonucleotide to Activate Dystrophin for Duchene Muscular Dystrophy 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Antisense Oligonucleotide to Inhibit HTT for Huntington's Disease 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Oligonucleotide for NeuroInflammation 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
nLife Therapeutics, S.L. - Pipeline Analysis 19
nLife Therapeutics, S.L. - Pipeline Products by Target 19
nLife Therapeutics, S.L. - Pipeline Products by Route of Administration 20
nLife Therapeutics, S.L. - Pipeline Products by Molecule Type 21
nLife Therapeutics, S.L. - Pipeline Products by Mechanism of Action 22
nLife Therapeutics, S.L. - Recent Pipeline Updates 23
nLife Therapeutics, S.L. - Locations And Subsidiaries 24
Head Office 24
Other Locations and Subsidiaries 24
Appendix 25
Methodology 25
Coverage 25
Secondary Research 25
Primary Research 25
Expert Panel Validation 25
Contact Us 25
Disclaimer 26

List of Tables
nLife Therapeutics, S.L., Key Information 5
nLife Therapeutics, S.L., Key Facts 5
nLife Therapeutics, S.L. - Pipeline by Indication, 2015 7
nLife Therapeutics, S.L. - Pipeline by Stage of Development, 2015 8
nLife Therapeutics, S.L. - Monotherapy Products in Pipeline, 2015 9
nLife Therapeutics, S.L. - Preclinical, 2015 10
nLife Therapeutics, S.L. - Discovery, 2015 11
nLife Therapeutics, S.L. - Pipeline by Target, 2015 19
nLife Therapeutics, S.L. - Pipeline by Route of Administration, 2015 20
nLife Therapeutics, S.L. - Pipeline by Molecule Type, 2015 21
nLife Therapeutics, S.L. - Pipeline Products by Mechanism of Action, 2015 22
nLife Therapeutics, S.L. - Recent Pipeline Updates, 2015 23
nLife Therapeutics, S.L., Other Locations 24

List of Figures
nLife Therapeutics, S.L. - Pipeline by Top 10 Indication, 2015 7
nLife Therapeutics, S.L. - Pipeline by Stage of Development, 2015 8
nLife Therapeutics, S.L. - Monotherapy Products in Pipeline, 2015 9
nLife Therapeutics, S.L. - Pipeline by Top 10 Target, 2015 19
nLife Therapeutics, S.L. - Pipeline by Top 10 Molecule Type, 2015 21
nLife Therapeutics, S.L. - Pipeline Products by Top 10 Mechanism of Action, 2015 22

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.